8-K: BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics reported its Q1 2025 financial results, highlighting progress in its NurOwn development program and the planned Phase 3b clinical trial for ALS.

Summary

• BrainStorm Cell Therapeutics announced its financial results for the first quarter ended March 31, 2025.
• The company is focused on initiating a Phase 3b trial to confirm NurOwn's efficacy in early-stage ALS patients and support a new BLA submission.
• An IND amendment for NurOwn has been submitted to the FDA, which includes updated documentation for regulatory compliance and trial integrity.
• The Phase 3b trial, named ENDURANCE, is listed on ClinicalTrials.gov (ID NCT06973629) and is expected to enroll approximately 200 ALS participants with early-stage disease.
• The primary efficacy endpoint will assess changes in ALSFRS-R scores from baseline to week 24.
• Successful completion of the double-blind part of the study (Part A) is expected to generate the clinical data to support a new BLA submission.
• NurOwn data was selected for presentation at the ISCT 2025 Meeting, highlighting the impact of the UNC13A genotype on clinical outcomes for ALS patients.
• Biomarker insights supporting NurOwn's mechanism and clinical impact were presented at the 2025 ALS Drug Development Summit.
• Cash, cash equivalents, and restricted cash were approximately $1.8 million as of March 31, 2025.
• Research and development expenditures, net, for the quarter ended March 31, 2025 were $1.3 million, compared to $1.0 million for the quarter ended March 31, 2024.
• General and administrative expenses for the quarter ended March 31, 2025 were approximately $1.8 million, compared to approximately $1.5 million for the quarter ended March 31, 2024.
• Net loss for the quarter ended March 31, 2025, was approximately $2.9 million, as compared to a net loss of approximately $3.4 million for the quarter ended March 31, 2024.
• Net loss per share for the three months ended March 31, 2025, and 2024 was $0.45 and $0.75, respectively.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in the NurOwn development program, the submission of the IND amendment, and the planned Phase 3b trial. However, the company's financial position and ongoing losses temper the overall sentiment.

Positives

• The company submitted an IND amendment to the FDA for NurOwn.
• The Phase 3b trial, ENDURANCE, is listed on ClinicalTrials.gov.
• NurOwn data was selected for presentation at the ISCT 2025 Meeting.
• The net loss decreased from $3.4 million in Q1 2024 to $2.9 million in Q1 2025.
• The company has ongoing support from the ALS community.

Negatives

• The company had a net loss of $2.9 million for the quarter ended March 31, 2025.
• Cash, cash equivalents, and restricted cash were approximately $1.8 million as of March 31, 2025.

Risks

• The company's ability to successfully complete the Phase 3b trial and obtain regulatory approval for NurOwn is subject to risks and uncertainties.
• The company's cash position of $1.8 million may require additional financing to support ongoing operations and clinical trials.
• The company's future interactions with the FDA may not have productive outcomes.

Future Outlook

BrainStorm is focused on initiating the Phase 3b trial for NurOwn in early-stage ALS patients and pursuing a new BLA submission upon successful completion of the trial.

Management Comments

• 'BrainStorm continues to make meaningful progress in advancing our NurOwn development program,' said Chaim Lebovits, President and Chief Executive Officer of BrainStorm.
• 'Our priority continues to be initiation of a Phase 3b trial, designed to confirm the products efficacy in early stage ALS patients and support a new BLA.'
• 'We have a clear path forward and ongoing support from the ALS community.'
• 'We believe that NurOwn, if approved, has the potential to become a valuable treatment option for ALS patients.'

Industry Context

BrainStorm is operating in the competitive field of neurodegenerative disease therapeutics, specifically targeting ALS. The company's NurOwn platform represents a novel approach using autologous stem cells, differentiating it from traditional pharmaceutical treatments. The successful completion of the Phase 3b trial and subsequent BLA submission are critical for the company to establish a foothold in the market.

Comparison to Industry Standards

• BrainStorm's approach of using autologous MSC-NTF cells is comparable to other cell therapy companies like Mesoblast, which is developing cell-based therapies for various inflammatory conditions.
• The Phase 3b trial design, including the primary endpoint of ALSFRS-R score changes, aligns with industry standards for ALS clinical trials, similar to those conducted by Amylyx Pharmaceuticals for Relyvrio.
• The company's focus on biomarker analysis and pharmacogenomics is in line with the growing trend of personalized medicine in the neurodegenerative disease space, as seen with companies like Denali Therapeutics.

Stakeholder Impact

• Positive impact on ALS patients if NurOwn is approved as a valuable treatment option.
• Potential benefits for shareholders through increased company value if the clinical trials are successful.
• Continued employment and research opportunities for employees.

Next Steps

• Initiate the Phase 3b clinical trial for NurOwn.
• Finalize clinical trial agreements with leading academic centers.
• Complete other necessary steps on trial execution and manufacturing.
• Pursue a new BLA submission upon successful completion of the Phase 3b trial.

Key Dates

Keywords

NurOwn, ALS, Phase 3b trial, IND amendment, FDA, Clinical trial, BrainStorm Cell Therapeutics, Financial results, Neurodegenerative diseases, Stem cell therapy